Therapeutic Effects of the Combination of Alpha-Lipoic Acid (ALA) and Coenzyme Q10 (CoQ10) on Cisplatin-Induced Nephrotoxicity

Table 1

Biochemistry data in the studied groups.

	Group I (N = 8)	Group II (N = 7)	Group III (N = 8)	Group IV (N = 8)	Group V (N = 8)	value in group II (cisplatin) versus other groups	value in group V (combination) versusgroups III, IV (monotherapy)
Urea (mg/dl); Mean ± SD	17.36 ± 4.61	227.7 ± 9.3	171.13 ± 6.19	162.8 ± 5.99	158.38 ± 6.86	0.00081	NS
Urinary albumin (mg/24 h); Mean ± SD	23.61 ± 11.3	478.6 ± 37.6	257.8 ± 12.1	289.13 ± 17.2	231 ± 4.59	0.00093	NS
Urinary total protein (mg/24 h); Mean ± SD	302.32 ± 62.9	3113.8 ± 118.4	1503.3 ± 69.4	1495.9 ± 106.4	1296.8 ± 75.4	0.00086	NS
Uric acid (mg/dl); Mean ± SD	3.7 ± 0.246	8.33 ± 0.164	3.92 ±0.0797	3.99 ± 0.111	3.69 ± 0.066	0.00075	NS
Creatinine (mg/dl); Mean ± SD	1.5 ± 0.541	6.01 ± 0.376	3.38 ± 0.227	3.801 ± 0.178	2.96 ± 0.097	0.00065	NS
Creatinine clearance (ml/min); Median(range)	0.361; 0.09–0.83	0.004; 0.002–0.006	0.0315; 0.028–0.038	0.0405; 0.022–0.054	0.1085; 0.096–0.199	0.00081	0.0176

Significant; NS: nonsignificant.